Is Austedo affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Austedo is affected by pharmacogenetics through the CYP2D6 gene. Your genotype for this gene can change how well Austedo works for you or how well you tolerate it. The strongest evidence level on this page is Strong, from the published guidelines shown below.
What's in Austedo
Deutetrabenazine Affected by CYP2D6
Affected by CYP2D6. Guidance from FDA, strong evidence.
Read the full deutetrabenazine genetics guideDeutetrabenazine phenotype recommendations
Published guidance from FDA on how deutetrabenazine should be dosed or substituted based on your CYP2D6 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Ultrarapid MetabolizerCYP2D6 | Your body processes deutetrabenazine faster than normal. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Normal MetabolizerCYP2D6 | Your body processes deutetrabenazine at a normal rate. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Intermediate MetabolizerCYP2D6 | Your body breaks down deutetrabenazine slightly slower than normal. The standard dose should work as expected. | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Poor MetabolizerCYP2D6 | Your body breaks down deutetrabenazine much more slowly than normal, causing the drug to build up and raising the risk of heart rhythm problems. A lower maximum dose is recommended. | FDA Do not exceed 36 mg a day (maximum single dose of 18 mg). |
Strong |
| IndeterminateCYP2D6 | The impact of your genotype on response to this drug is unknown | FDA Initiate therapy with recommended starting dose. |
Not rated |
| Not availableCYP2D6 | The impact of your genotype on response to this drug is unknown | FDA Initiate therapy with recommended starting dose. |
Not rated |
Source: FDA
The gene behind the guidance
CYP2D6 Cytochrome P450 2D6
CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).
The v4 report preserves the activity score used in its interpretation. Some medicines use a combined CYP2D6/CYP2C19 recommendation. CYP2D6 inhibitors can change functional metabolism; a genotype alone does not capture that effect.
See all drugs affected by CYP2D6Browse the full drug class: Movement disorder medications.
Related medications
Find out how your genetics affect Austedo
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.